BACK TO CONTENTS   |    PDF   |   


Title

Virtual Screening of IL-6 Inhibitors for Idiopathic Arthritis

 

Authors

Palak Shukla1, Ravina Khandelwal1, Diksha Sharma1, Anindya Dhar1, Anuraj Nayarisseri*,1,2,3,
Sanjeev Kumar Singh*,3

 

Affiliation

1In silico Research Laboratory, Eminent Biosciences, Mahalakshmi Nagar, Indore 452010, Madhya Pradesh, India; 2Bioinformatics Research Laboratory, LeGene Biosciences Pvt Ltd., Mahalakshmi Nagar, Indore - 452010, Madhya Pradesh, India; 3Computer Aided Drug Designing and Molecular Modelling Lab, Department of Bioinformatics, Alagappa University, Karaikudi-630 003, Tamil Nadu, India.

 

Email

Dr. Sanjeev Kumar Singh Email: skysanjeev@gmail.com; Dr. Anuraj Nayarisseri - Email: anuraj@eminentbio.com; *Corresponding authors:

 

Article Type

Research Article

 

Date

Received January 27, 2019; Revised February 10, 2019; Accepted February 19, 2019; Published February 28, 2019

 

Abstract

Juvenile idiopathic arthritis (JIA) is a heterogeneous disease characterized by the arthritis of unknown origin and IL6 is a known target for JIA. 20 known inhibitors towards IL-6 were screened and Methotrexate (MTX) having PubChem ID: 126941 showed high binding capacity with the receptor IL-6. The similarity searching with this compound gave 269 virtual screened compounds. The said screening presented 269 possible drugs having structural similarity to Methotrexate. The docking studies of the screened drugs separated the compound having PubChem CID: 122677576 (re-rank value of -140.262). Toxicity and interaction profile validated this compound for having a better affinity with the target protein. Conclusively, this study shows that according to ADMET profile and BOILED-Egg plot, the compound (PubChem CID: 122677576) obtained from Virtual Screen could be the best drug in future during the prevention of juvenile idiopathic arthritis. In the current study, the drug CID: 122677576 is a potent candidate for treating JIA. The pharmacophore study revealed that the drug CID: 122677576 is a non-inhibitor of CYP450 microsomal enzymes and was found to be non-toxic, similar to the established drug Methotrexate (CID: 126941). It has a lower LD50 value of 2.6698mol/kg as compared to the established compound whose LD50 value is 23.4955mol/kg. Moreover, the compound was found to be non-carcinogenic.

 

Keywords

IL-6, Idiopathic Arthritis, Molecular Docking, Virtual Screening

 

Citation

Shukla et al. Bioinformation 15(2): 121-130 (2019)

 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.